Drugs / AVT16
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06400719 | May → Nov 2024 | — | Alvotech Swiss AG | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06570772 | Sep 2024 → Nov 2025 | ulcerative colitis | Alvotech Swiss AG | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVT16 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06570772 ↗ |
| Route | Intravenous | “Single intravenous administration of 300mg of AVT16” NCT06400719 ↗ |